Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S Bianchi, R Bigazzi and VM Campese Kidney.

Slides:



Advertisements
Similar presentations
Treatment of Hypertension
Advertisements

Diabetes, Anemia and Chronic Kidney Disease Josephine Carlos-Raboca,M.D., F.P.S.E.M., Endocrinology, Diabetes and Metabolism Makati Medical Center.
Prescribing in Chronic Renal Disease. Who has chronic renal disease (CKD)? CKD stages 1-V How common is it? Creatinine v GFR Basic Principles Scenarios.
Mayrene Hernandez, DO Advanced ProMed Inc. Billing and Management Solutions Board Certified in Family Medicine Clinical Assistant Professor for NSU.
Efficacy of Sodium Bicarbonate Infusion in Reversal of Acute Renal Failure 1 NEPHRO 2014 June 25-28, 2014 Valencia, Spain.
CKD In Primary Care Dr Mohammed Javid.
National Institute for Health and Clinical Excellence.
Chapter 1: CKD in the General Population 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,
Mugendi AG, BPharm, MPharm (Clin Pharm). Comparison of the effects of losartan and enalapril on renal function in adults with chronic kidney disease at.
Chapter 2: Identification and Care of Patients With CKD 2014 ANNUAL DATA REPORT VOLUME 1: CHRONIC KIDNEY DISEASE.
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
Zehra Eren M.D. Nephrology Department. The Kidney in:  Congestive heart failure  Liver disease  Diabetes Mellitus  Systemic Vasculitis  İnfections.
Everything you wanted to know about CKD SUE GILDERSLEVE RENAL NURSE SPECISLIST.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
CGS BILLING SERVICE
CKD: the primary/secondary care interface Daniel Ford Consultant Renal Physician UHCW.
RENAL DISEASE IN DIABETES
Diabetic Nephropathy Yiming Lit, M.D. May 5, 2009.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
CASE 1. Donald is a 68 year-old man who is admitted to hospital via the Emergency Department one day, following a myocardial infarction. Subsequent investigation.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Stage 4 CKD presentation in patients over 75 Years Old differs from that in patients less than 75 Years of Age Hiromichi Suzuki, Tsutomu Inoue,Tomohiro.
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.
All things Renal Peer Support Zoulikha Zair. RAAS.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Table 1. Clinicopathological findings at biopsy Clinical Number of patients Age (years) Gender (%Male) eGFR (ml/min/1.73m 2 ) UPE (g/day) Serum albumin.
Chapter 2: Identification and Care of Patients With CKD 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Risk Involved with Dual RAAS Blockade in Kidney Disease Source: Bakris GL. Dual RAAS blockade is desirable in kidney disease: Con. Kidney Int. 2010;78:546–549.
Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with preserved Ejection Fraction Effect of Spironolactone.
Internal Medicine Workshop Series Laos September /October 2009.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Updates in Diabetic Nephropathy Rodica Pop-Busui, M.D., Ph.D Division of Metabolism, Endocrinology and Diabetes Michigan Comprehensive Diabetes Center.
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
The FRET Study Source: Inoue T, Ikeda H, Nakamura T, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin.
Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.
Risk Factors for Renal Dysfunction in Type 2 Diabetes: U.K. Prospective Diabetes Study 74 Ravi Retnakaran, Carole A Cull, Kerensa I Thorne, Amanda I Adler,
Supplementary Table 1 C min of Teicoplanin at 1 st and 2 nd TDM in patients with administration of additional loading dose on the 4 th day Teicoplanin.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.
Management of progression of CKD 순천향 대학병원 신장내과 강혜란.
A. Evaluation point Hospitalization (10 or more days)
The Significance of Albuminuria
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Effects of Uric acid- lowering therapy on renal outcomes: a systematic review and meta-analysis Nephrol Dial Transplant (2014) 29: Vaughan Washco.
Diuretics Thiazides are the preferred type of diuretic for treating hypertension, and all are equally effective in lowering blood pressure. In patients.
Elevated Circulating Levels of Inflammatory Markers in
Chapter 2: Identification and Care of Patients With CKD
2016 Annual Data Report, Vol 1, CKD, Ch 2
Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,
ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.
Progress and Promise in RAAS Blockade
Step Care Therapy for Hypertension in Diabetic Patients
National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient-centered.
Chapter 2: Identification and Care of Patients with CKD
Nat. Rev. Cardiol. doi: /nrcardio
Table of Contents Why Do We Treat Hypertension? Recommendation 5
The following slides are highlights of a report based on presentations at the Late-breaking Trials Session and a Satellite Symposium for the American College.
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease  S. Bianchi, R. Bigazzi, V.M. Campese 
Volume 62, Issue 4, Pages (October 2002)
Internal Medicine Workshop Series Laos September /October 2009
Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors  Barry M. Brenner, Joann Zagrobelny 
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.
Chapter 2: Identification and Care of Patients with CKD
Presentation transcript:

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S Bianchi, R Bigazzi and VM Campese Kidney International advance online publication 11 October 2006

Background  prevalence of CKD increasing result of an ongoing epidemic of obesity, metabolic syndrome, diabetes mellitus.  Several factors contribute to progression of CKD derangements of renal hemodynamics, vasoactive hormones such as angiotensin II and norepinephrine, cytokines, growth factors, oxidative stress, and inflammation

 RAAS important role in the progression of CKD  inhibition of RAAS with ACEIs, ARBs  retard CKD progression  “renoprotective effects” reduction of systemic arterial glomerular pr. inhibition of angiotensin II-related effects on mesangial cell proliferation and fibrosis.

 ‘aldosterone synthesis escape’ neither ACEIs nor ARBs progression of CKD ACEIs,ARBs not predictably suppress aldosterone leaving detrimental effects of aldosterone unabated  clinical evidence for a role of aldosterone in CKD progression is scanty  prospective, randomized open-label study to evaluate the effects of spironolactone

MATERIALS AND METHODS

82 patients (conventional therapy) 83 patients (spironolactone 25 mg/day) enrolled 165 CKD pts (106 males and 59 females) baseline evaluation each clinic visit at 1, 3, 6, 9, 12 months BP, heart rate, blood sample spot morning urine samples

Exclusion criteria  diabetes mellitus, renovascular or malignant HTN  secondary glomerular disease, malignancies  myocardial infarction  cerebrovascular accident within the 6 mo.  congestive heart failure, hepatic dysfunction  potassium >5 mEq/l, eGFR <30 ml/min/1.73m 2  History of allergy to ACEIs or ARBs  patients treated with steroids, NSAIDs, immunosuppressant

RESULTS

Table 1. Clinical characteristics at baseline of pts treated with conventional therapy and conventional therapy plus spironolactone 25 mg/day

Table 2. BP, estimated GFR and serum potassium levels at baseline and during f/u in pts treated with conventional therapy and conventional therapy plus spironolactone

Table 3. Effect of spironolactone on proteinuria in pts with eGFR 60 ml/min/1.73m2

Table 4. Effect of spironolactone 25 mg/day on renal function in pts with eGFR 60 ml/min/1.73m 2

Table 5. Clinical characteristics at baseline and end of study in pts treated with spironolactone in addition to ACEIs alone, ARBs alone, or a combination of ACEIs and ARBs

Figure 1. This slide shows the percent reduction of proteinuria from baseline in pts treated with spironolactone (25 mg/day) in addition to conventional therapy divided on basis of their eGFR ( 60 ml/min/1.73m 2 ).

Figure 2. This slide shows the percent decline in eGFR in pts treated with spironolactone and conventional therapy.

Figure 3. This slide shows the regression line between baseline plasma aldosterone levels and proteinuria in the 165 pts included in the study (r=0.766, P<0.0001).

Conclusion  spironolactone may reduce proteinuria and retard renal progression in chronic kidney disease patients.